It’s Not All Negative: Antibody Drug Conjugates in HER-2 Low Breast Cancer

<p>Brianna Chambers, PharmD describes the landscape for HER-2 low classification in the treatment of breast cancer.</p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes.</a></p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>